Case Report

Two cases of gastrointestinal stromal tumor of the small intestine with liver and bone metastasis

Meryem Aktan, Mehmet Koc, Berrin Benli Yavuz, Gul Kanyilmaz

Meram Faculty of Medicine, Department of Radiation Oncology, Necmettin Erbakan University, 42090 Konya, Turkey
Correspondence to: Meryem Aktan. Meram Faculty of Medicine, Department of Radiation Oncology, Necmettin Erbakan University, 42090 Konya, Turkey. Email: meryemaktan@gmail.com.

Abstract: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. These tumors most commonly occur in the stomach (60%), jejunum and ileum (30%). Metastasis is characteristically the malignant behavior of the GISTs. GISTs most frequently metastasize to the liver and peritoneum, whereas bone and lung metastases are uncommon sites. Here, we described two cases of bone and liver metastases in patients with advanced GISTs. Both of them showed liver metastasis at disease presentation and bone metastasis in early time after the diagnosis. Bone metastases involved the lumbar spine and right femur in first patient and L2 vertebral body in the second case. All of the lesions presented a lytic pattern. These cases are presented because of the rare incidence of bone metastasis from GISTs in clinical practice despite the shortage of available data on the sensitivity and specificity of bone scintigraphy and PET-CT.

Keywords: Gastrointestinal stromal tumor (GIST); bone; metastasis

Submitted Jul 07, 2015. Accepted for publication Sep 21, 2015.
doi: 10.3978/j.issn.2305-5839.2015.09.46
View this article at: http://dx.doi.org/10.3978/j.issn.2305-5839.2015.09.46

Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Most gastrointestinal soft tissue neoplasms were classified as leiomyomas, schwannomas, leiomyoblastomas, or leiomyosarcomas. They are now classified as GISTs based on immunohistochemistry, histology and molecular study. They originate from the multipotential mesenchymal stem cells and differentiate to interstitial Cajal’s cells (1).

Based on size, mitotic index and anatomic location, GISTs are categorized as low, intermediate, and high risk. GISTs are generally defined as c-KIT (CD117; a tyrosine kinase receptor) positive tumors with a characteristic set of histologic features. CD34 (70%), variable expression of smooth muscle actins (SMA) (20-30%) and S100 protein (10%) are commonly positive and desmin is almost uniformly negative (only 2-4% of GISTs are positive) (2).

The incidence of GIST is in the range of 20 to 40 cases per million. Over 90% of GISTs occur in adults over 40 years old, in a median age of 63 years and rarely in children in the second decade (<1%). Most GISTs are benign; malignant tumors account for 20-30% of cases. The most common location of GIST is stomach (50-60%) and small intestine (30-40%). Other less common locations are duodenum (4-5%), rectum (4%), colon and appendix (1-2%), and esophagus (<1%). Patients have different symptoms, such as abdominal pain and swelling, weakness and anemia (3).

Cases

Case 1

A 56-year-old male patient was examined with an abdominal swelling. The examinations and abdomen CT showed the presence of a mass in small intestine and a lesion in the liver. It was unclear whether the tumor was primary or metastatic. Sectional resection of the jejunum, ileum and liver biopsy was performed on September 2012. Histopathological
examination showed epithelioid and spindle cells, 12 mitoses at 50x magnification, infiltrative growth pattern and mild cytological atypia. There was no necrosis. In the immunochemical analysis, CD 117, CD 34, SMA, EMA, CD 99 and Pan CK were positive, CK 5/6 and Glut 1 were focally positive, S100 and desmin were negative, and the Ki-67 index was 80%. Tumor diameter was 9 cm, muscle and serosal invasion were positive and the tumor persisted at the surgical margin. Pathological examination showed high-risk gastrointestinal stromal tumor of the small intestine and liver metastasis. After the surgery, Imatinib mesylate 400 mg/day was given to the patient as an adjuvant treatment. Four months after the operation, the patient had a complaint of pain in dorsal and lumbar area and right hip. MR imaging of the thoracal-lumbar vertebra and hip showed that there were metastatic lesions on the L1-L3 vertebral body and proximal of right femur. Furthermore, a PET-CT scan was performed on the patient. The results showed the existence of multiple metastatic lesions in the liver, a relapse lesion in small intestine area and increased activity in the right femur and L1-L3 vertebral body (SUV_{max}: 12.64). PET-CT images of patient showed in Figure 1. Palliative radiotherapy was performed at a fraction of 3 Gray (Gy) with a total dose of 30 Gy on the bone metastasis in the right femur and L1-L3 vertebral body. Afterwards, zoledronic acid 4 mg i.v. was started. Pain complaint significantly decreased after the radiotherapy. We can not take any new images, because he was died 45 days after the radiotherapy.

**Discussion**

Metastasis is characteristically the malignant behavior of the GIST. GISTs most frequently make metastasis to the liver and peritoneum, whereas bone and lung metastases are uncommon sites (4).

Jati et al. reported 190 GIST patients, six (3.2%) had bone metastases, four patients had multiple bone metastases, and two patients had a solitary metastasis (5).

Di Scioscio et al. reported 3 GIST cases with bone metastasis and two of them showed bone and liver metastasis at the time of disease presentation (6). In the
study of Schuler et al., out of the 309 consecutive patients with metastatic GIST, 17 (5.5%) were identified to have bone metastases, 5/17 patients had synchronous metastatic disease and 17/17 patients had hepatic manifestations (7).

Our patients had liver metastasis at the time of disease diagnosis and bone metastasis in early time after the diagnosis. In our previous case study, we showed one case of GIST with bone metastasis approximately one year after diagnosis (8). CT, MRI, and especially PET-CT can be used for staging in the diagnosis and metastases scanning of GIST because of the metastasis at the same time of diagnosis and may enhance the diagnosis of tumor bone metastasis and provide more information for cancer treatment (9). Initial reports suggest F-FDG PET-CT in staging, evaluation of early response to imatinib mesylate therapy and follow-up in recurrent or metastatic GIST (10). PET-CT shows the increased metabolic activity of tumor cells and can detect both osteoblastic and osteolytic lesions at an earlier stage and useful in characterizing bone lesions that require biopsy (11). In case one, we used PET-CT after diagnosis and imatinib treatment. The results showed multiple metastatic lesions in the liver, bone metastasis and a relapse lesion in small intestine.

Limited data can be found in literature on the treatment of bone metastases in GISTs. Imatinib mesylate (Kit-selective tyrosine kinase inhibitor) can be used in the treatment of advanced, recurrent, unresectable or metastatic GIST. Imatinib mesylate has also proven efficacy in bone metastases of GIST (12,13). Other treatments include radiofrequency ablation and embolization. Radiotherapy can be used in patients with bone metastasis for palliative reasons (8).

Zoledronic acid is a bisphosphonate and penetrates osteoclast cells selectively and promotes their apoptosis by reducing bone resorption. That is the current standard therapy for osteoporosis and is used to combat hypercalcemia and bone metastases from solid tumors in the colon, breast, lung, prostate and renal cell carcinoma (14). We used zoledronic acid in both cases and the previous case.

**Conclusions**

In our opinion, more attention should be paid to the diagnosis of bone metastases from GISTs in clinical practice despite the shortage of available data on the sensitivity and specificity of bone scintigraphy and PET-CT. These imaging studies must be done especially for the high-risk GISTs during the diagnosis.

**Acknowledgements**

None.

**Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

**References**

2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn

---

*Figure 2* (A) L2 metastasis of case 2; (B) primary tumor of case 2; (C) liver metastasis of case 2.
Aktan et al. Gastrointestinal stromal tumor with bone metastasis
